Mark W. Zimmerman
ORCID: 0000-0003-2489-3889Also affiliated with Dana-Farber Cancer Institute, Foghorn Therapeutics (United States)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Papers
Driven by 13 papers. Top paper: “ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression”.
Ting Tao, Brian J. Abraham, Adam D. Durbin, Mark W. Zimmerman, Cigall Kadoch +2 more
Shuning He, Radosław P. Nowak, Jinhua Wang, Mark W. Zimmerman, Cong Fu +7 more
Hui Shi, Luca Mariani, Brian J. Abraham, Adam D. Durbin, Mark W. Zimmerman +9 more
Adam D. Durbin, Shuning He, Felix Oppel, Hui Shi, Ting Tao +8 more
Tingjian Wang, Virangika K. Wimalasena, Mark W. Zimmerman, Deyao Li, Neekesh V. Dharia +24 more
Adam D. Durbin, Shuning He, Felix Oppel, Hui Shi, Ting Tao +8 more
Mark W. Zimmerman, Brian J. Abraham, Adam D. Durbin, Noha A.M. Shendy
Shuning He, Alla Berezovskaya, Adam D. Durbin, Neekesh V. Dharia, Kimberly Stegmaier +10 more
Nicole Prutsch, Shuning He, Mark W. Zimmerman, Yosef Landesman, A. Thomas Look +1 more
Hui Shi, Ting Tao, Derek A. Oldridge, Adam D. Durbin, Brian J. Abraham +10 more
Nicole Prutsch, Shuning He, Mark W. Zimmerman, Yosef Landesman, A. Thomas Look +1 more
Sukriti Bagchi, Zhihui Liu, Hsien-Chao Chou, Man Xu, Ming Sun +8 more
Shuning He, Alla Berezovskaya, Adam D. Durbin, Neekesh V. Dharia, Kelsey A. Maher +10 more